Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).
Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively.
Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.